{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:41:11Z","timestamp":1790095271533,"version":"4.0.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.clinthera.2019.12.002","type":"journal-article","created":{"date-parts":[[2020,1,16]],"date-time":"2020-01-16T17:34:18Z","timestamp":1579196058000},"page":"44-59.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research"],"prefix":"10.1016","volume":"42","author":[{"given":"Jessica","family":"Ochalek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Lomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2019.12.002_bib1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jval.2017.12.012","article-title":"A\u00a0health economics approach to US value assessment frameworks-introduction: an ISPOR Special Task Force Report [1]","volume":"21","author":"Neumann","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2019.12.002_bib2","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jval.2017.12.006","article-title":"An overview of value, perspective, and decision context\u2014a health economics approach: an ISPOR Special Task Force Report [2]","volume":"21","author":"Garrison","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2019.12.002_bib3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jval.2017.12.008","article-title":"Objectives, budgets, thresholds, and opportunity costs\u2014a health economics approach: an ISPOR Special Task Force Report [4]","volume":"21","author":"Danzon","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2019.12.002_bib4","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jval.2016.11.021","article-title":"Developing a value framework: the need to reflect the opportunity costs of funding decisions","volume":"20","author":"Sculpher","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2019.12.002_bib5","first-page":"717","article-title":"A\u00a0framework for assessing the performance of health systems","volume":"78","author":"Murray","year":"2000","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.clinthera.2019.12.002_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1744133116000049","article-title":"Cost-effectiveness thresholds in health care: a bookshelf guide to their meaning and use","volume":"11","author":"Culyer","year":"2016","journal-title":"Heal Econ Policy Law"},{"key":"10.1016\/j.clinthera.2019.12.002_bib7","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1017\/S0266462318000612","article-title":"Cost, context, and decisions in health economics and health technology assessment","volume":"34","author":"Culyer","year":"2018","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.clinthera.2019.12.002_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hec.3831","article-title":"A\u00a0cost-effectiveness threshold based on the marginal returns of cardiovascular hospital spending","volume":"28","author":"van Baal","year":"2019","journal-title":"Health Econ"},{"key":"10.1016\/j.clinthera.2019.12.002_bib9","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40273-017-0606-1","article-title":"Cost-effectiveness thresholds: the past, the present and the future","volume":"36","author":"Thokala","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2019.12.002_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta19140","article-title":"Methods for the estimation of the National Institute for health and care Excellence cost-effectiveness threshold","volume":"19","author":"Claxton","year":"2015","journal-title":"Health Technol Assess (Rockville)"},{"key":"10.1016\/j.clinthera.2019.12.002_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40273-017-0585-2","article-title":"Estimating the reference incremental cost-effectiveness ratio for the Australian health system","volume":"36","author":"Edney","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2019.12.002_bib12","author":"Vallejo-Torres"},{"key":"10.1016\/j.clinthera.2019.12.002_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2019.04.1926","article-title":"Estimating the marginal productivity of the English National health service from 2003 to 2012","author":"Lomas","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2019.12.002_bib14","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1002\/hec.3946","article-title":"The marginal benefits of healthcare spending in The Netherlands: estimating cost-effectiveness thresholds using a translog production function","volume":"28","author":"Stadhouders","year":"2019","journal-title":"Health Econ"},{"key":"10.1016\/j.clinthera.2019.12.002_bib15","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.jval.2016.02.017","article-title":"Country-level cost-effectiveness thresholds: initial estimates and the need for further research","volume":"19","author":"Woods","year":"2016","journal-title":"Value Heal"},{"key":"10.1016\/j.clinthera.2019.12.002_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-000964","article-title":"Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data","volume":"3","author":"Ochalek","year":"2018","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.clinthera.2019.12.002_bib17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/hec.1157","article-title":"Government health expenditures and health outcomes","volume":"16","author":"Bokhari","year":"2007","journal-title":"Health Econ"},{"key":"10.1016\/j.clinthera.2019.12.002_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/07474938.2016.1114205","article-title":"Inference in the presence of redundant moment conditions and the impact of government health expenditure on health outcomes in England","volume":"36","author":"Andrews","year":"2017","journal-title":"Econom Rev"},{"key":"10.1016\/j.clinthera.2019.12.002_bib19","series-title":"Global Burden of Disease Study 2015 (GBD 2015) Data Resources | GHDx","year":"2018"},{"key":"10.1016\/j.clinthera.2019.12.002_bib20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0277-9536(87)90167-5","article-title":"International cross-section analysis of the determination of mortality","volume":"25","author":"Gravelle","year":"1987","journal-title":"Soc Sci Med"},{"key":"10.1016\/j.clinthera.2019.12.002_bib21","series-title":"Assessing the Impact of Health Care Expenditures on Mortality Using Cross-Country Data. York","author":"Nakamura","year":"2016"},{"key":"10.1016\/j.clinthera.2019.12.002_bib23","series-title":"Assessing Health Opportunity Costs for the Canadian Health Care Systems","author":"Ochalek","year":"2018"},{"key":"10.1016\/j.clinthera.2019.12.002_bib24","doi-asserted-by":"crossref","unstructured":"Cameron D, Ubels J, Norstr\u00f6m F. Global Health Action. On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review. Glob Health Action. 1447;11. doi:10.1080\/16549716.2018.1447828.","DOI":"10.1080\/16549716.2018.1447828"},{"key":"10.1016\/j.clinthera.2019.12.002_bib25","series-title":"Guide to the Technology Appraisal Process (Reference N0514)","year":"2004"},{"key":"10.1016\/j.clinthera.2019.12.002_bib26","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/bmj.329.7459.224","article-title":"National Institute for clinical Excellence and its value judgments","volume":"329","author":"Rawlins","year":"2004","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2019.12.002_bib27","series-title":"First Report of the Health Committee 2007-2008","year":"2007"},{"key":"10.1016\/j.clinthera.2019.12.002_bib28","series-title":"NICE Response to the First Report of Session 2007\u20132008","year":"2008"},{"key":"10.1016\/j.clinthera.2019.12.002_bib29","series-title":"The Government\u2019s Response to the Health Select Committee\u2019s First Report of Session 2007\u201308 on the National Institute for Health and Care Excellence","year":"2008"},{"key":"10.1016\/j.clinthera.2019.12.002_bib30","series-title":"ACC\/AHA Statement on Cost\/value Methodology in Clinical practice Guidelines and performance Measures: A Report of the American College of Cardiology\/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines","volume":"63","author":"Anderson","year":"2014"},{"key":"10.1016\/j.clinthera.2019.12.002_bib31","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clinthera.2019.12.002_bib33","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s40273-014-0162-x","article-title":"Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines","volume":"32","author":"Newall","year":"2014","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2019.12.002_bib34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","article-title":"Thresholds for the cost-effectiveness of interventions: alternative approaches","volume":"93","author":"Marseille","year":"2015","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.clinthera.2019.12.002_bib35","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/heapol\/czw096","article-title":"Understanding and improving the one and three times GDP per capita cost-effectiveness thresholds","volume":"32","author":"Robinson","year":"2017","journal-title":"Health Policy Plan"},{"key":"10.1016\/j.clinthera.2019.12.002_bib36","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2471\/BLT.15.164418","article-title":"Cost-effectiveness thresholds: pros and cons","volume":"94","author":"Bertram","year":"2016","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.clinthera.2019.12.002_bib38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.15171\/ijhpm.2017.47","article-title":"Measuring the benefits of healthcare: DALYs and QALYs\u2014does the choice of measure matter? A case study of two preventive interventions","volume":"7","author":"Augustovski","year":"2018","journal-title":"Int J Heal Policy Manag"},{"key":"10.1016\/j.clinthera.2019.12.002_bib39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.healthpol.2008.12.010","article-title":"Searching for cost effectiveness thresholds in the NHS","volume":"91","author":"Appleby","year":"2009","journal-title":"Health Policy (New York)"},{"key":"10.1016\/j.clinthera.2019.12.002_bib40","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1108\/JHOM-11-2012-0225","article-title":"Tackling disinvestment in health care services","volume":"27","author":"Daniels","year":"2013","journal-title":"J\u00a0Health Organ Manag"},{"key":"10.1016\/j.clinthera.2019.12.002_bib41","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jval.2018.02.013","article-title":"Surveying the cost-effectiveness of the 20 procedures with the largest public health services waiting lists in Ireland: implications for Ireland's cost-effectiveness threshold","volume":"21","author":"Chen","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2019.12.002_bib42","series-title":"International Health Economics Association","article-title":"Measuring opportunity costs of health technology adoption as morbidity and mortality of the uninsured","author":"Vanness","year":"2017"},{"key":"10.1016\/j.clinthera.2019.12.002_bib43","series-title":"Priced Out\u00a0: The Economic and Ethical Costs of","author":"Reinhardt","year":"2019"},{"key":"10.1016\/j.clinthera.2019.12.002_bib46","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"13","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2019.12.002_bib44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","article-title":"Defining elements of value in health care\u2014a health economics approach: an ISPOR Special Task Force Report [3]","volume":"21","author":"Lakdawalla","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2019.12.002_bib45","doi-asserted-by":"crossref","DOI":"10.1007\/s40258-019-00481-8","article-title":"Striving for a societal perspective: a framework for economic evaluations when costs and effects fall on multiple sectors and decision makers","author":"Walker","year":"2019","journal-title":"Appl Health Econ Health Policy"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291819305855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:51:28Z","timestamp":1758963088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291819305855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0149291819305855"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.12.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reflecting the Health Opportunity Costs of Funding Decisions Within Value Frameworks: Initial Estimates and the Need for Further Research","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2019.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}